MedTrace Logo

Effect of Azilsartan on Aldosterone in Postmenopausal Females

NCT01774591 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-11-09

Study results available
· View outcomes & findings →

Summary

The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.

Conditions

Interventions

DRUG

Azilsartan medoximil

All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.

DRUG

Placebo

All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • George Bakris, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-11-30
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01774591 on ClinicalTrials.gov